within Pharmacolibrary.Drugs.D_Dermatologicals.D07A_CorticosteroidsPlain.D07AA02_Hydrocortisone;

model Hydrocortisone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 4.444444444444444e-06,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.037,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.063,
    k12 = 5.833333333333334e-06,
    k21 = 5.833333333333334e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Hydrocortisone</td></tr><tr><td>ATC code:</td><td>D07AA02</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>37.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>16.0</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Hydrocortisone is a synthetic form of cortisol, a glucocorticoid hormone produced by the adrenal cortex. It is primarily used as an anti-inflammatory and immunosuppressive agent in various conditions such as adrenal insufficiency, allergic reactions, autoimmune disorders, and skin diseases. Hydrocortisone is approved and widely used both systemically and topically in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>Hamitouche, N, et al., &amp; Laviolle, B (2017). Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers. <i>The AAPS journal</i> 19(3) 727–735. DOI:<a href=\"https://doi.org/10.1208/s12248-016-0041-9\">10.1208/s12248-016-0041-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28083797/\">https://pubmed.ncbi.nlm.nih.gov/28083797</a></p></li><li><p>Vincze, I, et al., &amp; Kopitkó, C (2022). Assessment of Antibiotic Pharmacokinetics, Molecular Biomarkers and Clinical Status in Critically Ill Adults Diagnosed with Community-Acquired Pneumonia and Receiving Intravenous Piperacillin/Tazobactam and Hydrocortisone over the First Five Days of Intensive Care: An Observational Study (STROBE Compliant). <i>Journal of clinical medicine</i> 11(14) –. DOI:<a href=\"https://doi.org/10.3390/jcm11144140\">10.3390/jcm11144140</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35887904/\">https://pubmed.ncbi.nlm.nih.gov/35887904</a></p></li><li><p>Knych, HK, et al., &amp; Kass, PH (2019). Pharmacokinetics of intravenous flumetasone and effects on plasma hydrocortisone concentrations and inflammatory mediators in the horse. <i>Equine veterinary journal</i> 51(2) 238–245. DOI:<a href=\"https://doi.org/10.1111/evj.13002\">10.1111/evj.13002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30080272/\">https://pubmed.ncbi.nlm.nih.gov/30080272</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.D.D07AA02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Hydrocortisone;
